In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies

Gene Therapy

Volumn 12, Issue 12, 2005, Pages 988-998

  Lamikanra, A ^a,c   Myers, K A ^a   Ferris, N ^b   Mitrophanous, K A ^a   Carroll, M W ^a,d  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d Molecular Nature Limited   (United Kingdom)

Author keywords

Antivector response; EIAV; Long term expression; Single chain antibody; VSV G

Indexed keywords

HYBRID PROTEIN; ONCOFETAL ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CANCER; CANCER THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; EQUINE INFECTIOUS ANEMIA VIRUS; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE;

ANIMALS; ANTIBODIES; ANTIGENS, CD80; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOGLOBULIN FC FRAGMENTS; INFECTIOUS ANEMIA VIRUS, EQUINE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASMS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 21344460517     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302484     Document Type: Article

References (41)

1. Bicker R, Kessler T, Berdel WE, Mesters RM. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep 2003; 10: 1915-1917.
2. Martinelli G et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003; 123: 271-277.
3. McCafferty J, Hoogenboom H, Chiswell D (eds). Antibody Engineering. Oxford University Press: Oxford, 1996, (Hames B, ed. A Practical Approach, Vol 169).
4. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.
5. Hornick JL et al. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997; 89: 4437-4447.
6. Cooke SP et al. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem 2002; 13: 7-15.
7. Whittington HA, Ashworth LJ, Hawkins RE. Recombinant actenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Therapy 1998; 5: 770-777.
8. Arafat WO et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy 2002; 9: 256-262.
9. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
10. Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
11. Konishi H et al. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther 1998; 9: 235-248.
12. Coffin JM, Hughes SH, Varmus HE eds. Retroviruses. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1997.
13. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
14. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
15. Olsen JC. EIAV, CAEV and other lentivirus vector systems. Somat Cell Mol Genet 2001; 26: 131-145.
16. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002; 21: 937-951.
17. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Therapy 1998; 5: 1481-1487.
18. Mitrophanous K et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Therapy 1999; 6: 1808-1818.
19. Azzouz M et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22: 10302-10312.
20. Bienemann AS et al. Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol Ther 2003; 7: 588-596.
21. Southall PJ et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990; 61: 89-95.
22. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992; 66: 867-869.
23. Myers KA et al. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem 1994; 269: 9319-9324.
24. Myers KA et al. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins. Cancer Gene Ther 2002; 9: 884-896.
25. Mazarakis ND et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-2121.
26. Brattain MG et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142-2146.
27. Hole N, Stern PL. A 72 kDa trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988; 57: 239-246.
28. Adams GP et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998; 58: 485-490.
29. Coll JM. The glycoprotein G of rhabdoviruses. Arch Virol 1995; 140: 827-851.
30. Mulryan K et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1: 1129-1137.
31. Busch DH, Pilip IM, Vijh S, Pamer EG. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 1998; 8: 353-362.
32. Martin-Rendon E et al. New methods to titrate EIAV-based lentiviral vectors. Mol Ther 2002; 5: 566-570.
33. Follenzi A et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
34. Pan D et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 2002; 6: 19-29.
35. Tsui LV et al. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002; 20: 53-57.
36. Follenzi A et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2003; 30: 30.
37. Freer G et al. Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen. J Virol 1994; 68: 3650-3655.
38. Burkhart C et al. Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus. J Virol 1994; 68: 1573-1580.
39. VandenDriessche T et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822.
40. Baekelandt V et al. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Therapy 2003; 10: 1933-1940.
41. Yamada K, McCarty DM, Madden VJ, Walsh CE. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 2003; 34: 1074-1078, 1080.